Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Recurrence 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Fluorouracil 13Cisplatin 7Radiotherapy 6Specimen Handling 5Mitomycin 5Capecitabine 5pembrolizumab 4dehydroftorafur 4Radiation 4Drug Therapy 4Cetuximab 4Radiotherapy, Intensity-Modulated 3Paclitaxel 3Nivolumab 3Magnetic Resonance Spectroscopy 3Carboplatin 3Biopsy 3tislelizumab 2durvalumab 2aldesleukin 2VGX-3100 2Platinum 2Mitozytrex 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 21,2-diaminocyclohexaneplatinum II citrate 2toripalimab 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1spartalizumab 1rocakinogene sifuplasmid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anus Neoplasms × MEDI0457 × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡